In a mouse model of spontaneous mammary tumorigenesis, a DC-based vaccine specifically targeting HER-2/neu led to the production of anti-neu antibodies along with T-cell mediated expression of interferon-γ, resulting in tumor regression (76). Here, ERBB2 is linked to neoplasm.